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exclusion criteria. The combined odds ratio was 1.72 (95% CI: 1.432 to 2.070), indicating 
the odds of fetal malformation is higher among women taking antidepressants than 
those not receiving SSRIs. In the pairwise analysis, 2 of the 14 pairwise comparisons 
were statistically significant: fluoxetine compared to control (OR 1.774, 95% CI 1.008 
to 2.925); paroxetine compared to control (OR 1.752, 95% CI 1.057 to 2.953). The result-
ing pairwise odds ratios suggested a lowest odds of malformation to highest odds 
was citalopram, sertraline, paroxetine, fluoxetine. ConClusions: The risk of mal-
formation is an important consideration when treating pregnant women. This study 
suggests that there is an increase in the odds of fetal malformation when exposed 
to SSRIs in utero during the period of organogenesis. The risk appears to be highest 
with fluoxetine and paroxetine, and lower for citalopram.
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objeCtives: The costs of schizophrenia in Austria are high and new long acting 
injectable (LAI) antipsychotics might be able to reduce costs due to a reduction 
of hospital stays. We aim to estimate budget effects of the introduction of a new 
LAI (Paliperidone Palmitate) in Austria. Methods: A budget impact analysis was 
conducted that took direct costs of illness into account (i.e. costs for inpatient 
and outpatient services and drug costs). We used official Austrian remuneration 
prices as input parameters. The robustness of the model was checked by means 
of deterministic sensitivity analyses with regard to switch rates to Paliperidone 
Palmitate and rehospitalisation rates. Results: According to our calculations, 
direct total costs of schizophrenia in Austria reach € 254.36 million a year. The 
drug costs are € 26.14 million and the costs for inpatient and outpatient services 
are € 228.22 million. Within the next five years, drug costs will slightly decrease to 
€ 25.77 million due to a bigger market share of generic Quetiapine which offsets 
the higher drug costs of Paliperidon palmitate. The use of Quetiapine is associ-
ated with a higher rate of rehospitalisation. Therefore, costs for inpatient and 
outpatient services will increase to € 228.65 million, which results in an overall 
effect of € 60,000 additional costs compared to the situation without paliperidone 
palmitate. ConClusions: The introduction of a new treatment of schizophrenia 
in Austria is budget neutral.
PMH19
aSSoCIatIon Between CognItIve funCtIon and 3 MontH HealtH Care 
CoStS aMong PatIentS InItIatIng an antIdePreSSant for dePreSSIve 
dISorder In an aMBulatory Care SettIng
Kurlander J.L.1, Walker V.1, Essoi B.1, Samp J.2, Akhras K.S.2, Yang J.2
1OptumInsight, Eden Prairie, IL, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, 
USA
objeCtives: Depression is associated with reduced cognitive function and signifi-
cant health care costs; however, the extent to which these two are related remains 
unclear. This study compared follow-up health care costs for major depressive dis-
order patients with and without cognitive dysfunction after antidepressant (AD) 
initiation. Methods: A large US health plan affiliated with OptumInsight was used 
to identify depressed patients with a newly prescribed AD who could be surveyed 
to assess cognitive function. Patients with neurological diseases associated with 
cognitive dysfunction were excluded. Patients were mailed a survey invitation and 
consent form. Patients maintained eligibility by confirming a depressive diagno-
sis and no excluding diagnoses. Consenting, eligible patients were interviewed by 
telephone and completed 4 cognitive function tests. Patients were classified as 
“cognitive normal (CN)” or “cognitive dysfunction (CD)” based on test scores relative 
to normative data. All-cause health care costs in the 3 months post-AD initiation 
were calculated from pharmacy and medical claims. T-tests compared 3-month 
costs of CN versus CD. Gamma models with log link compared health care costs 
between CD and CN patients, adjusting for race, sex, age, education, employment, 
depression severity, and comorbidities. Results: A total of 13,537 patients were 
invited to participate in the study and 564 patients maintained eligibility and com-
pleted the study. Patients were mostly female (80%), mean age was 41 years, 98% 
had a high school degree or higher, and 84% were employed. A total of 45% (n= 255) 
met criteria for CD. Mean health care costs were $4,996 for all patients. Costs were 
$6,457 for the CD group compared to $3,787 for the CN (p = 0.038). In the gamma 
models with costs as the outcome, CD patients had costs 1.43 times higher than CN 
patients (95% CI: 1.13, 1.81). ConClusions: In this study population, health care 
costs were significantly higher in patients with cognitive dysfunction compared to 
those without cognitive dysfunction.
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objeCtives: To assess the economic burden and health care utilizations of 
patients diagnosed with post-traumatic stress disorder (PTSD) in the U.S. veteran 
population. Methods: Patients diagnosed with PTSD were identified (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis 
code 309.81) from the Veterans Health Administration (VHA) dataset from October 
01, 2009 through September 30, 2011. The first diagnosis date was designated as the 
index date. A comparator group was created by identifying patients without PTSD 
but with the same age, region, gender and index year, and who were matched by 
baseline Charlson Comorbidity Index. A randomly chosen index date served to 
severity of depression on these outcomes. These preliminary results need to be 
confirmed on the full dataset.
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objeCtives: To identify factors associated with early response at 4 weeks of treat-
ment with olanzapine and to assess whether early response is associated with 
better longer-term outcomes for patients with schizophrenia in China. Methods: 
A post-hoc analysis was conducted using data from the Chinese schizophrenia 
subgroup (n= 330) of a multicountry, 6-month, prospective, observational study of 
outpatients with schizophrenia/bipolar mania who were initiated or switched to oral 
olanzapine. Stepwise logistic regression controlling for baseline clinical character-
istics, participation in weight education program at baseline, and compliance with 
antipsychotics over first 4 weeks of olanzapine treatment was used to identify fac-
tors associated with early response. Mixed Models Repeated Measures with baseline 
covariates were used to compare outcomes over time between early responders and 
early non-responders to olanzapine. Results: A total of 130 patients (40%) achieved 
early response. The models revealed that significant factors associated with a higher 
likelihood of achieving early response were higher CGI-Sevirity score (OR= 1.51, 95% 
CI: 1.15-1.97), fewer years since first diagnosis (OR= 0.94, 95% CI: 0.90-0.98), a greater 
number of social interactions (OR= 1.22, 95% CI: 1.05-1.40), participation in a weight 
education program (OR= 1.81, 95% CI: 1.04-3.15) at study entry, and high medication 
compliance with antipsychotics during the first 4 weeks of treatment (OR= 2.98, 95% 
CI: 1.59-5.58). When compared to early non-responders, early responders achieved a 
significantly higher endpoint response and significantly greater symptom improve-
ment at end point (CGI-Severity) and a greater improvement in level of functional 
outcomes (all p< 0.05). ConClusions: High levels of compliance to prescribed 
antipsychotic and participation in a weight education program were associated with 
early response in schizophrenia patients in China. Early response was associated 
with greater improvement in symptomatic, functional and quality-of-life outcomes 
at 6 months compared to early non-response. Current findings are consistent with 
previous research outside of China.
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objeCtives: Patients with major depressive disorder (MDD) frequently suffer from 
concomitant pain symptoms, which are associated with higher depression sever-
ity and worse quality of life. We describe the baseline factors associated with pain 
persistence in patients with MDD during a 3-month follow-up period. Methods: 
Patients from Asia (n= 909) presenting with a new or first episode of MDD were 
enrolled in a 3-month prospective observational study. This report analyzes the 
709 (78%) patients assessed at baseline and 3 months. Demographics, depressive 
symptoms (Hamilton Depression Scale), overall severity (Clinical Global Impression 
Severity score), somatic symptoms (Somatic Symptom Inventory) and quality of 
life (Euro QOL -5D) were assessed. Logistic regression models were fitted to assess 
the relationship between baseline factors and pain persistence during follow-
up. Results: Of the 709 patients analyzed , 349 (49%) had pain at baseline. Forty 
three per cent of the patients (151) having pain at baseline still presented with pain 
at 3-months. Patients with persistent pain had more frequently suffered from previ-
ous MDD episodes (54% vs 39%) , were less likely to be older than 60 (11 vs. 21%), and 
had a higher number of medical comorbid conditions (14% vs 5% with two or more 
co-morbidities). The logistic model adjusting for other baseline covariates confirmed 
these results. ConClusions: A high proportion of patients with depression who 
presented with pain at baseline still suffered from pain symptoms at 3 months. A 
history of depression and the presence of other medical conditions were risk factors 
for pain persistence at 3-months.
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objeCtives: Assessing the safety of selective serotonin reuptake inhibitor (SSRI) 
use during pregnancy is complicated, especially given the array of treatment option. 
The objective of this study was to evaluate the risks of fetal malformation of SSRI 
use during pregnancy. Methods: A search for prospective studies evaluating fetal 
malformation with maternal use of citalopram, fluoxetine, paroxetine, or sertraline 
was conducted using the databases of MEDLINE, PsycINFO and EMBASE for the period 
of 1974 to March 21, 2013. The key terms used were: ‘serotonin reuptake inhibitors’, 
‘pregnancy’, ‘prospective studies’. The inclusion criteria in addition to prospective 
studies included: 1) malformation outcome; 2) citalopram, fluoxetine, paroxetine, 
and/or sertraline; 3) drug exposure in first trimester; and 4) compared to control 
group of either ‘no SSRI exposure’ or ‘nonteratogenic agents’. The exclusion criteria 
included: 1) evaluation of SSRI as a drug class, and 2) venlafaxine or bupropion. A 
Bayesian random-effects indirect treatment comparison model was used to perform 
the analysis. Results: The search resulted in 64 articles. Eight articles met inclusion/
